Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer’s disease patients

[1]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[2]  P. Averback,et al.  A randomized controlled trial of prednisone in Alzheimer’s disease , 2000, Neurology.

[3]  J. Yesavage,et al.  Combined assessment of tau and neuronal thread protein in Alzheimer’s disease CSF , 2000, Neurology.

[4]  Kaj Blennow,et al.  Measurement of Apolipoprotein E (apoE) in Cerebrospinal Fluid , 2000, Neurochemical Research.

[5]  K. Yanagisawa,et al.  Age-Dependent Decline in the Apolipoprotein E Level in Cerebrospinal Fluid from Control Subjects and Its Increase in Cerebrospinal Fluid from Patients with Alzheimer’s Disease , 2000, European Neurology.

[6]  H. Soininen,et al.  Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease , 2000, Neuroscience Letters.

[7]  K. Blennow,et al.  Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment , 1999, Neuroscience Letters.

[8]  Jellinger Ka.  What is new in degenerative dementia disorders , 1999 .

[9]  T. Lehtimäki,et al.  Longitudinal stability of CSF tau levels in Alzheimer patients , 1999, Biological Psychiatry.

[10]  Hiroyuki Arai,et al.  Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease , 1999, Neuroscience Letters.

[11]  K. Blennow,et al.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.

[12]  R. D'Hooge,et al.  Unchanged levels of interleukins, neopterin, interferon-γ and tumor necrosis factor-α in cerebrospinal fluid of patients with dementia of the Alzheimer type , 1999, Neurochemistry International.

[13]  J. Overmier,et al.  Inflammatory pathogenesis in Alzheimer's disease: biological mechanisms and cognitive sequeli , 1999, Neuroscience & Biobehavioral Reviews.

[14]  P. Deyn,et al.  Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.

[15]  H. Möller,et al.  Oligoclonal bands and blood--cerebrospinal-fluid barrier dysfunction in a subset of patients with Alzheimer disease: comparison with vascular dementia, major depression, and multiple sclerosis. , 1999, Alzheimer disease and associated disorders.

[16]  K. Davis,et al.  CSF beta-amyloid, cognition, and APOE genotype in Alzheimer’s disease , 1999, Neurology.

[17]  M. Rossor,et al.  Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease , 1999, Neuroscience Letters.

[18]  A. Smith,et al.  Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. , 1998, Alzheimer disease and associated disorders.

[19]  E. Corder,et al.  The role of APOE polymorphisms in late-onset dementias , 1998, Cellular and Molecular Life Sciences CMLS.

[20]  S. Hirai,et al.  Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan , 1998 .

[21]  J. Kaye,et al.  High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. , 1998, Archives of neurology.

[22]  S. Hirai,et al.  Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease , 1998, Journal of the Neurological Sciences.

[23]  M. Esiri,et al.  Accuracy of Clinical Operational Diagnostic Criteria for Alzheimer’s Disease in Relation to Different Pathological Diagnostic Protocols , 1998, Dementia and Geriatric Cognitive Disorders.

[24]  K. Blennow,et al.  A population study on blood-brain barrier function in 85-year-olds , 1998, Neurology.

[25]  D. Blacker,et al.  The genetics of Alzheimer disease: current status and future prospects. , 1998, Archives of neurology.

[26]  Giovanni B. Frisoni,et al.  Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' , 1998 .

[27]  A D Roses,et al.  Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. , 1998, The New England journal of medicine.

[28]  C. Hock,et al.  Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients , 1997, Neuroscience Letters.

[29]  L. Wahlund,et al.  Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein , 1997, Neuroscience Letters.

[30]  H. Möller,et al.  Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease 1 Paper will be presented in part (Abstract) at the Meeting of the Society for Neuroscience, New Orleans, LA, USA in October 1997. 1 , 1997, Neuroscience Letters.

[31]  D. Dickson,et al.  The Pathogenesis of Senile Plaques , 1997, Journal of neuropathology and experimental neurology.

[32]  S. Hahne,et al.  Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls , 1997, Neuroscience Letters.

[33]  I. Skoog,et al.  Apolipoprotein E in cerebrospinal fluid in 85-year-old subjects. Relation to dementia, apolipoprotein E polymorphism, cerebral atrophy, and white matter lesions. , 1997, Archives of neurology.

[34]  G. Siest,et al.  Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease , 1997, Journal of the Neurological Sciences.

[35]  A. Delacourte,et al.  Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease , 1996, Neuroscience Letters.

[36]  K. Jellinger,et al.  Intra vitam lumbar cerebrospinal fluid and serum and postmortem ventricular immunoreactive apolipoprotein E in patients with Alzheimer's disease. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[37]  H. Wiśniewski,et al.  Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease: correlations with amyloid load in the brain. , 1996, Archives of neurology.

[38]  K. Jellinger,et al.  Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[39]  Peter Riederer,et al.  Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients , 1995, Neuroscience Letters.

[40]  R. Wolfert,et al.  Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease , 1995 .

[41]  Á. Hernanz,et al.  Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[42]  C. Hock,et al.  Increased levels of τ protein in cerebrospinal fluid of patients with alzheimer's disease—correlation with degree of cognitive impairment , 1995, Annals of neurology.

[43]  T. Hasegawa,et al.  Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia , 1995, Neuroscience Letters.

[44]  J. Poirier.  Apolipoprotein E in animal models of CNS injury and in alzheimer's disease , 1994, Trends in Neurosciences.

[45]  K. Blennow,et al.  Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease. , 1994, Neuroreport.

[46]  D. Schenk,et al.  Concentrations of amyloid-β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease , 1994, Neuroscience Letters.

[47]  J. Howbert,et al.  Interleukin-6 secretion from human astrocytoma cells induced by substance P , 1994, Journal of Neuroimmunology.

[48]  G. Small,et al.  Central Nervous System IgG Synthesis Rates in Alzheimer Disease: Possible Differences in Early‐Onset and Late‐Onset Subgroups , 1994, Alzheimer Disease and Associated Disorders.

[49]  Paul L. Wood,et al.  Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1β or IL-1RA but increases in the associated acute phase proteins IL-6, α2-macroglobulin and C-reactive protein , 1993, Brain Research.

[50]  S. Sorbi.  Molecular genetics of Alzheimer’s disease , 1993, Aging.

[51]  L. Mucke,et al.  Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[52]  M. Goedert.  Tau protein and the neurofibrillary pathology of Alzheimer's disease , 1993, Trends in Neurosciences.

[53]  Jan Six,et al.  Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme‐Linked Immunosorbent Assay , 1993 .

[54]  Á. Hernanz,et al.  Relationship of interleukin-1β and β 2-microglobulin with neuropeptides in cerebrospinal fluid of patients with dementia of the Alzheimer type , 1993, Journal of Neuroimmunology.

[55]  T. Wisniewski,et al.  Apolipoprotein E : binding to soluble Alzheimer's β-amyloid , 1993 .

[56]  P. Malek-Ahmadi.  Substance P and neuropsychiatric disorders: An overview , 1992, Neuroscience & Biobehavioral Reviews.

[57]  R. Fishman.  Cerebrospinal Fluid in Diseases of the Nervous System , 1992 .

[58]  Thomas Wisniewski,et al.  Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid , 1992, Neuroscience Letters.

[59]  H. Hatanaka,et al.  Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures , 1991, Neuroscience.

[60]  P. Mecocci,et al.  Blood‐brain‐barrier in a geriatric population: barrier function in degenerative and vascular dementias , 1991, Acta neurologica Scandinavica.

[61]  M. Beal,et al.  An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[62]  U. Schreiter-Gasser,et al.  Interleukin‐6 and α‐2‐macroglobulin indicate an acute‐phase state in Alzheimer's disease cortices , 1991, FEBS letters.

[63]  V. Armstrong,et al.  Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid. , 1991, Clinica chimica acta; international journal of clinical chemistry.

[64]  E. Otomo,et al.  Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease , 1991, Brain Research.

[65]  D. Kirschner,et al.  Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. , 1990, Science.

[66]  R. Lindenberg.  Neuropathological diagnosis of Alzheimer disease. , 1990, Journal of neuropathology and experimental neurology.

[67]  K. Blennow,et al.  Intra‐Blood-Brain‐Barrier Synthesis of Immunoglobulins in Patients with Dementia of the Alzheimer Type , 1990, Alzheimer Disease and Associated Disorders.

[68]  R. Zinkernagel,et al.  On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases , 1989, European journal of immunology.

[69]  M. Rossor,et al.  THE MOLECULAR-GENETICS OF ALZHEIMERS-DISEASE , 1989 .

[70]  C. Hack,et al.  SERUM LEVELS OF INTERLEUKIN-6 AND ACUTE PHASE RESPONSES , 1987, The Lancet.

[71]  H. Reiber,et al.  Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. , 1987, Clinica chimica acta; international journal of clinical chemistry.

[72]  S. Rapoport,et al.  CSF and serum concentrations of albumin and IgG in Alzheimer's disease , 1987, Neurobiology of Aging.

[73]  C. Gandolfo,et al.  The integrity of the blood—Brain barrier in Alzheimer's type and multi-infarct dementia evaluated by the study of albumin and IgG in serum and cerebrospinal fluid , 1985, Journal of the Neurological Sciences.

[74]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[75]  R. Ihl,et al.  Integrity of the blood-CSF barrier in dementia of Alzheimer type: CSF/serum ratios of albumin and IgG , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[76]  L. Wilkinson,et al.  The stimulus-induced release of 5-hydroxytryptamine and tryptophan from superfused rat brain synaptosomes , 2005, Journal of Neural Transmission.

[77]  J. Warter,et al.  Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus , 2004, Journal of Neurology.

[78]  J. Bauer,et al.  Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients , 2004, Acta Neuropathologica.

[79]  K. Jellinger.  What is new in degenerative dementia disorders? , 1999, Wiener klinische Wochenschrift.

[80]  K. Jellinger,et al.  Biological markers for the diagnosis of Alzheimer's disease. , 1998, Journal of neural transmission. Supplementum.

[81]  K. Blennow,et al.  Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing. , 1998, Journal of neural transmission. Supplementum.

[82]  D. Galasko.  Cerebrospinal fluid levels of Aβ42 and tau: potential markers of Alzheimer’s disease , 1998 .

[83]  H. Arai,et al.  Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease. , 1997, Gerontology.

[84]  P. Riederer,et al.  Neurochemical abnormalities in Alzheimer's disease and Parkinson's disease--a comparative review. , 1997, Journal of neural transmission. Supplementum.

[85]  G. Valenti.  Neuropeptide changes in dementia: pathogenetic implications and diagnostic value. , 1996, Gerontology.

[86]  J. Rogers,et al.  Neuroimmune Mechanisms in Alzheimer Disease Pathogenesis , 1994, Alzheimer disease and associated disorders.

[87]  M. Vandermeeren,et al.  Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. , 1993, Journal of neurochemistry.